SAN DIEGO — Kidney transplant patients who move into the newly recognized microvascular inflammation category under the revised definition have a moderate risk of poor allograft outcomes, a large study …
Rejection
-
-
Researchers recently uncovered important insights into a newly defined rejection entity in kidney transplantation, which may improve risk stratification of patients after transplantation. The research will be presented at ASN …
-
Heart Transplantation
Antibody treatment before surgery may prevent heart transplant rejection
by Science Blogby Science BlogIn mice, an approach that blocks inflammation extends organ survival from about a week to more than two months A new study by scientists at Cincinnati Children's Hospital shows there …
-
Currently we must have an exact match to receive an organ from a donor, especially kidneys, but that may no longer be an issue.
-
Lung Transplantation
Montgomery County woman with cystic fibrosis needs second double lung transplant after rejection
PHILADELPHIA (CBS) — A young woman from Montgomery County is fighting desperately for her life: She needs a lung transplant but most hospitals are turning her down. Following tubing to …
-
Kidney Transplantation
HI-Bio Announces Positive Results from Phase 2 Study of Felzalutamab for Late Antibody-Mediated Rejection in Kidney Transplant Patients
by HI-Bioby HI-Bio82% (n=9/11) of patients who received felzaltamab experienced resolution of symptoms. Antibody-mediated rejection The proportion of patients meeting the Banff criteria in the 24-week biopsy was significantly increased compared to …
-
Ankit Bharat, MBBS, the Harold L. and Margaret N. Methods Professor of Surgery and chief of the Department of Thoracic Surgery, is co-author of the study published in the Journal …
-
Lung Transplantation
TFF Pharmaceuticals Announces Interim Data from a Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) to Prevent Lung Transplant Rejection at the 44th International Society for Heart and Lung Transplantation (ISHLT) 2024 Annual Meeting
TFF Pharma Co., Ltd. Oral Presentation Presenting Latest Data from a Phase 2 Study Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC FORT WORTH, Texas, March 25, …
-
News
Eledon Pharmaceuticals Announces Enrollment of 12th Participant in Phase 2 BESTOW Study Evaluating Tegopulvert for Prevention of Organ Rejection
Eredon Pharmaceuticals Co., Ltd. IRVINE, Calif., March 25, 2024 (Globe Newswire) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the registration of 12 pharmaceutical companies.th On March 23, 2024, …